In short
This article explores the use of Nicotinamide BP, a form of vitamin B3, in clinical trials as part of a multivitamin formulation. While the primary focus of the trial is on a different drug (eplontersen) for treating transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), Nicotinamide BP is included as one of the active substances in a multivitamin capsule used in the study. We'll examine the potential benefits and implications of using this vitamin combination in clinical research for heart-related conditions.
At a glance
- Study Type
- Open-label extension study
- Main Condition
- Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
- Primary Drug
- Eplontersen
- Multivitamin Used
- Concavit Capsules
- Nicotinamide BP Role
- One of the active substances in Concavit
- Administration Route
- Oral use
- Maximum Daily Dose
- 3000 IU
- Maximum Treatment Period
- 36 months
- Primary Objectives
- Evaluate safety and tolerability of extended eplontersen dosing
- Secondary Objectives
- Assess efficacy parameters and changes in biomarkers
What is Nicotinamide BP?
Nicotinamide BP, also known as niacinamide, is a form of vitamin B3. It is one of the active ingredients found in Concavit Capsules, a multivitamin supplement. The "BP" in the name stands for "British Pharmacopoeia," which indicates that the substance meets specific quality standards.
Uses of Nicotinamide BP
Nicotinamide BP is primarily used as a vitamin supplement. It plays several important roles in the body, including:
- Supporting cellular energy production
- Helping maintain healthy skin
- Contributing to the proper functioning of the nervous system
- Assisting in DNA repair
In the context of the clinical trial mentioned, Nicotinamide BP is part of a multivitamin supplement given to patients with a condition called Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM). This is a serious heart condition where abnormal proteins build up in the heart, affecting its function.
How Nicotinamide BP is Administered
In the clinical trial, Nicotinamide BP is administered as part of Concavit Capsules, which are soft capsules taken orally. The dosage mentioned in the trial is approximately 3000 IU (International Units) of vitamin A or a similar dose, which may be taken either as a single vitamin A supplement or as part of a multivitamin.
Clinical Trials and Research
The clinical trial mentioned is studying a drug called eplontersen for the treatment of ATTR-CM. While Nicotinamide BP is not the main focus of the study, it is included as part of the vitamin supplementation given to patients.
The main objectives of this trial are:
- To evaluate the long-term safety and tolerability of eplontersen in patients with ATTR-CM
- To assess various efficacy parameters after extended dosing with eplontersen
It's important to note that this trial is an extension study, meaning it follows up on patients who participated in an earlier phase of research.
Safety and Side Effects
Nicotinamide BP, as part of a multivitamin supplement, is generally considered safe when taken as directed. However, as with any medication or supplement, there can be potential side effects or interactions. The clinical trial is closely monitoring patients for any adverse events.
Important Considerations
If you are considering taking Nicotinamide BP or are participating in a clinical trial involving this supplement, keep the following in mind:
- Always follow your healthcare provider's instructions regarding dosage and administration.
- Inform your doctor about all medications and supplements you are taking to avoid potential interactions.
- If you experience any unusual symptoms or side effects, report them to your healthcare provider immediately.
- Remember that while vitamin supplements can be beneficial, they are not a substitute for a balanced diet and healthy lifestyle.
It's crucial to understand that the information provided here is based on a specific clinical trial and may not apply to all situations. Always consult with a healthcare professional for personalized medical advice.